News Releases September 19, 2022 Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock Read more August 29, 2022 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more August 15, 2022 Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress Read more August 15, 2022 Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958 Read more August 11, 2022 Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022 Read more June 29, 2022 Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735 Read more June 1, 2022 Ventyx Biosciences to Participate in the Jefferies Healthcare Conference Read more May 12, 2022 Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress Read more May 9, 2022 Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer Read more May 5, 2022 Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022 Read more Current page 1 Page 2 Next page › Last page » Displaying 1 - 10 of 18
